Dovitinib

Also known as: TKI-258, CHIR-258, CHIR258, 4-Amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one, UNII I35H55G906, Dovitinib (TKI-258, CHIR-258)

Dovitinib (CAS 405169-16-6) is a compound in the Organic Compounds category listed in the Jingsj chemical database. It has the molecular formula C21H21FN6O and a molecular weight of 392.429 g/mol. Key property: a density of 1.4±0.1 g/cm3. No supplier offers are currently listed; request a quote. Record last updated Aug 21, 2026.

CAS No.: 405169-16-6
Jingsj CID: J-1962553-7
Molecular Formula: C₂₁H₂₁FN₆O
Molecular Weight: 392.429 g/mol
Category: Organic Compounds
Last updated: 8/21/2026

Request MSDS / TDS

No offers for this compound yet.

Request a quote

Physicochemical Properties

Density	1.4±0.1 g/cm3
Exact Mass	392.176086
PSA	94.04000
LogP	1.59
Refractive Index	1.691
Storage Conditions	-20°C

Activity & Biological Data

Target	FGFR1:8 nM (IC50) FGFR3:9 nM (IC50) VEGFR1:1 nM (IC50) VEGFR2:13 nM (IC50) VEGFR3:8 nM (IC50) PDGFRα:27 nM (IC50) PDGFRβ:210 nM (IC50) FLT3:1 nM (IC50) c-Kit:2 nM (IC50)
Additional Information	[1]. Trudel S, et al. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood. 2005, 105(7), 2941-2948. [2]. Huynh H, et al. Dovitinib demonstrates antitumor and antimetastatic activities in xenograft models of hepatocellular carcinoma. J Hepatol. 2012, 56(3), 595-601. [3]. Lee Y, et al. A Receptor Tyrosine Kinase Inhibitor, Dovitinib (TKI-258), Enhances BMP-2-Induced Osteoblast Differentiation In Vitro. Mol Cells. 2016 May 31;39(5):389-94 [4]. Chon HJ, et al. Traf2- and Nck-interacting kinase (TNIK) is involved in the anti-cancer mechanism of dovitinib in human multiple myeloma IM-9 cells. Amino Acids. 2016 Jul;48(7):1591-9.

Target

FGFR1:8 nM (IC50) FGFR3:9 nM (IC50) VEGFR1:1 nM (IC50) VEGFR2:13 nM (IC50) VEGFR3:8 nM (IC50) PDGFRα:27 nM (IC50) PDGFRβ:210 nM (IC50) FLT3:1 nM (IC50) c-Kit:2 nM (IC50)

Additional Information

[1]. Trudel S, et al. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood. 2005, 105(7), 2941-2948. [2]. Huynh H, et al. Dovitinib demonstrates antitumor and antimetastatic activities in xenograft models of hepatocellular carcinoma. J Hepatol. 2012, 56(3), 595-601. [3]. Lee Y, et al. A Receptor Tyrosine Kinase Inhibitor, Dovitinib (TKI-258), Enhances BMP-2-Induced Osteoblast Differentiation In Vitro. Mol Cells. 2016 May 31;39(5):389-94 [4]. Chon HJ, et al. Traf2- and Nck-interacting kinase (TNIK) is involved in the anti-cancer mechanism of dovitinib in human multiple myeloma IM-9 cells. Amino Acids. 2016 Jul;48(7):1591-9.

Frequently Asked Questions

What is the CAS number of Dovitinib?

The CAS number of Dovitinib is 405169-16-6.

What are the molecular formula and molecular weight of Dovitinib?

Dovitinib has molecular formula C21H21FN6O and molecular weight 392.429 g/mol.

What are the upstream and downstream products of Dovitinib?

For Dovitinib, Upstream Products: ethyl 2-(5-(4-methylpiperazin-1-yl)-1H-benzo[d]imidazol-2-yl)acetate, 2-Amino-6-fluorobenzonitrile, 1-Methylpiperazine.

Data compiled from public chemical databases such as PubChem and supplier catalogs; supplier offers are provided by suppliers.

Last updated: 8/21/2026

How to cite: Jingsj. "Dovitinib (CAS 405169-16-6)". Jingsj Chemical Database. https://www.jingsj.com/compound/J-1962553-7 (accessed 2026-11-09).

Data for reference only; verify product details with suppliers before purchase.